(untitled)
Julie Teruya‐Feldstein(Memorial Sloan Kettering Cancer Center), R. S. K. Chaganti(Leukemia and Lymphoma Society), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Jane Houldsworth(Icahn School of Medicine at Mount Sinai), Gerard Donnelly(Memorial Sloan Kettering Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Vadim Dyomin(Memorial Sloan Kettering Cancer Center), Abhijith Hegde(Memorial Sloan Kettering Cancer Center), André Goy(Hackensack University Medical Center), Frédéric Gilles(Memorial Sloan Kettering Cancer Center), Jing Qin(Memorial Sloan Kettering Cancer Center), Howard T. Thaler(Memorial Sloan Kettering Cancer Center), Kenneth O. Lloyd(Memorial Sloan Kettering Cancer Center)
Cited by 4
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k